Currently, phase II of IPH4102 is ongoing to confirm IPH4102 activity alone or in combination with chemotherapy in SS patients and other TCL subtypes that express KIR3DL2 (TELLOMAK, NCT03902184). Here, KIR3DL2 is linked to synovial sarcoma.